Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Aging Stereotypes and Prodromal Alzheimer's Disease (AGING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03138018
Recruitment Status : Recruiting
First Posted : May 3, 2017
Last Update Posted : July 25, 2018
Sponsor:
Information provided by (Responsible Party):
Assistance Publique Hopitaux De Marseille

Brief Summary:
Because of the lengthening of life expectancy, more and more people are concerned with the effects of aging on their mental faculties (e.g., memory decline) and with the possibility of getting Alzheimer's Disease (AD) or other forms of dementia. This increasing awareness of AD has already resulted in a growing demand for neuropsychological testing. AD's research also emphasizes the need for early screening to improve the prediction of the disease progression and the efficacy of any future therapy. Such a drive to screen for pre-dementia raises the challenging issue of frontline identification of individuals in the preclinical or early clinical stages of AD. Mild Cognitive Impairment (MCI) is typically considered to be the prodromal state of AD, and is therefore at the core of the drive for early screening. Moreover, Pre-MCI so called SCI (Subjective Cognitive Impairment) can precede AD for 15 years. However, many individuals diagnosed with MCI do not convert to AD, some remaining stable and others even reversing back to normal (with rates of reversion to normal varying from 4.5% to as high as 53%). This over-diagnosis bias, which has been largely overlooked, is at the core of the present project at the interface of human and life sciences. Here, we argue that an important source of overdiagnosis in the prodromal state of AD comes from negative aging stereotypes (e.g., the culturally shared beliefs that aging inescapably causes severe cognitive decline and diseases such as AD) that permeate neuropsychological screening. There is ample evidence in the laboratory that such stereotypes contribute to the differences observed in the healthy population between younger and older adults in explicit memory tasks. Additionally, three pilot (lab) studies specifically conducted for the present ANR project showed that the threat of being judged stereotypically undermines the controlled use of memory of healthy older adults and simultaneously intensifies their automatic response tendencies, resulting in impaired memory performance. The present proposal goes several steps further by examining for the first time whether aging stereotypes are powerful enough to implicitly permeate the clinical neuropsychological testing and thus inflate memory deficits in older adults judged "at risk" (based on either epidemiological criteria or memory complaints), resulting in false-positive detection of SCI and MCI. This provocative hypothesis will be tested while 1) using biomarkers of neurodegeneration to distinguish false-positives from true MCI, and 2) using biomarkers of stress to examine whether and how aging stereotypes can lead to acute physiological stress during neuropsychological testing. This innovative project has the potential to offer new recommendations to improve the diagnosis accuracy of prodromal state of AD, with positive consequences for older people's wellbeing.

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment (MCI) Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: The Potential Impact of Aging Stereotypes in the Assessment of Memory Deficits and Screening for Prodromal State of Alzheimer's Disease
Actual Study Start Date : July 6, 2018
Estimated Primary Completion Date : July 1, 2023
Estimated Study Completion Date : July 1, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Standard instruction Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Neuropsychological tests

Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Neuroimaging biomarkers of neurodegeneration

Experimental: Reduced threat instruction Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Neuropsychological tests

Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Neuroimaging biomarkers of neurodegeneration




Primary Outcome Measures :
  1. Neuropsychological tests [ Time Frame: 48 months ]
    Neuropsychological battery used for the diagnosis of Mild Cognitive Impairment (MCI, amnestic single or multiple domain)


Secondary Outcome Measures :
  1. Neuroimaging biomarkers of neurodegeneration [ Time Frame: 48 months ]
    Structural MRI (Hippocamp) and Florbetapir© PET (β-amyloid deposition)

  2. Physiological stress [ Time Frame: 48 months ]
    cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).

  3. Self-report questionnaires [ Time Frame: 48 months ]
    Vulnerability factors for stereotyping threat effects are assessed

  4. Heart rate variability (thin elasticized heart rate transmitter belt), [ Time Frame: 48 months ]
    Physiological stress

  5. Skin conductance (wristwatch) [ Time Frame: 48 months ]
    Physiological stress

  6. Salivary biomarkers [ Time Frame: 48 months ]
    cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be at least 50 years old
  • Patients must report memory complaints
  • Patients must show signs of MCI (amnestic single or multiple domain) on the following short cognitive tests

Exclusion Criteria:

  • Probable Alzheimer's Disease according to NINCDS-ADRDA criteria (MA patients will be excluded from the study because false-positive errors only concern MCI status, not AD)
  • Psychiatric disorders (schizophrenia, bipolar disorder)
  • Cranial trauma
  • Developmental pathologies
  • Depression (score greater than or equal to 10 on GDS)
  • Psychotropic medication if modified in the last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03138018


Contacts
Layout table for location contacts
Contact: Bernard MICHEL, PH 491744675 ext +33 bmichel@ap-hm.fr
Contact: Isabelle REGNER, PhD 413550993 ext +33 isabelle.regner@univ-amu.fr

Locations
Layout table for location information
France
Assistance Publique Hôpitaux de Marseille Recruiting
Marseille, France, 13354
Contact: Bernard MICHEL, PH    491744675 ext +33    bmichel@ap-hm.fr   
Principal Investigator: Bernard MICHEL, PH         
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Investigators
Layout table for investigator information
Study Director: Urielle DESALBRES, Director ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE

Layout table for additonal information
Responsible Party: Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier: NCT03138018     History of Changes
Other Study ID Numbers: 2016-45
IDRCB Number ( Other Identifier: 2017-A00946-47 )
First Posted: May 3, 2017    Key Record Dates
Last Update Posted: July 25, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders